Platelets in Wiskott-Aldrich syndrome: Victims or executioners?

L Sereni, MC Castiello, A Villa

Research output: Contribution to journalArticlepeer-review


Microthrombocytopenia is the clinical hallmark of WAS, a rare X-linked immunodeficiency that is characterized by eczema, autoimmunity, and cancer susceptibility. This disease is caused by mutations in the WAS gene, which is expressed in hematopoietic cells and regulates actin cytoskeleton remodeling thereby modulating various cellular functions, including motility, immunologic synapse assembly, and signaling. Despite extensive studies that have provided great insight into the relevance of this molecule to innate and cellular immunity, the exact mechanisms of microthrombocytopenia in WAS are still unknown. This review focuses on the recent progress made in dissecting the pathogenesis of platelet defects in patients with WAS and their murine counterparts. In parallel, we will provide an overview of the state-of-the art platelets as immune modulators at the interface between hemostasis and the immune system, which suggests that these cells may have a direct role in the pathogenesis of immune dysregulation in WAS. ©2017 Society for Leukocyte Biology
Original languageEnglish
Pages (from-to)577-590
Number of pages14
JournalJournal of Leukocyte Biology
Issue number3
Publication statusPublished - 2018


Dive into the research topics of 'Platelets in Wiskott-Aldrich syndrome: Victims or executioners?'. Together they form a unique fingerprint.

Cite this